好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Evaluating the Effects of Endovascular Interventions on the Incidence of Epileptiform Abnormalities in Aneurysmal Subarachnoid Hemorrhage Patients
Neuro Trauma and Critical Care
P9 - Poster Session 9 (5:00 PM-6:00 PM)
18-009

To evaluate EEG responses to endovascular interventions used to prevent and treat delayed cerebral ischemia

Prior work has associated the development of delayed cerebral ischemia in hospitalized aneurysmal subarachnoid hemorrhage patients with increased incidence of inter-ictal continuum abnormalities and epileptiform discharges on long-term EEG monitoring.

However, to our knowledge no group has compared the frequencies of these EEG abnormalities before and after endovascular interventions used to prevent and treat delayed cerebral ischemia.

We performed a single-center retrospective analysis of EEG recordings from aneurysmal subarachnoid hemorrhage patients admitted to our Neuro-ICU.

EEGs from 50 patients (mean age 56.3 ± 11.6 years, 38 female, median Hunt-Hess 3 and modified Fisher 4) who received a total of 86 endovascular interventions with intra-arterial verapamil (mean dose 22.7 ± 10.3 mg, 9 with angioplasty) were processed using the recently developed Morgoth algorithm for automated detection of EEG abnormalities.

Time intervals from 8 to 2 hours before procedure start and 2 to 8 hours after procedure end were compared for the rates of seconds with high probability of epileptiform activity (LPDs, GPDs, or LRDA), GRDA, seizures, and spikes using matched-paired T-tests.

As compared to the preprocedural time interval, the postprocedural time interval showed a 15.1% average decrease in the frequency of epileptiform activity (p = 0.14), an 8.9% average decrease in the frequency of seizure (p = 0.54), and a 26.3% average decrease in the frequency of spikes (p = 0.06).

The frequency of GRDA stayed essentially constant across time intervals (p = 0.97).

While the decreases seen in the detected incidences of epileptiform abnormalities were individually non-significant, their collective trend suggests a potential benefit of endovascular interventions in reducing neurophysiologic dysfunction in patients at risk for or actively developing delayed cerebral ischemia.

Further work is needed to characterize these findings on the individual patient level.

Authors/Disclosures
Rafael Maarek
PRESENTER
Mr. Maarek has received research support from National Heart Lung & Blood Institute. Mr. Maarek has received research support from Richard K. Gershon Endowed Medical Student Research Fellowship.
Kaitlyn Stoehr, MS5 Ms. Stoehr has nothing to disclose.
Sithmi M. Jayasundara Miss Jayasundara has nothing to disclose.
David J. Vargas Estrella Mr. Vargas Estrella has nothing to disclose.
Rachel S. Choi (Yale School of Medicine) Ms. Choi has nothing to disclose.
Amedeo Rapuano (Yale New Haven Hospital) Amedeo Rapuano has nothing to disclose.
Zhongwei Jin, MD Ms. Jin has nothing to disclose.
jin jing, PhD Dr. jing has received publishing royalties from a publication relating to health care.
Tao Sun Prof. Sun has nothing to disclose.
Andrew B. Koo, MD Dr. Koo has nothing to disclose.
Yilun Chen (Yale University) Ms. Chen has nothing to disclose.
Jessica Magid-Bernstein, MD, PhD (Yale School of Medicine) Dr. Magid-Bernstein has nothing to disclose.
Lena O'Keefe, MD Dr. O'Keefe has nothing to disclose.
Farhad Bahrassa (Yale Department of Neurosurgery) Farhad Bahrassa has nothing to disclose.
Ryan Hebert Ryan Hebert has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cerenovus .
M. B. Westover, MD, PhD (MGH) Dr. Westover has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Beacon Biosignals. Dr. Westover has stock in Beacon Biosignals. The institution of Dr. Westover has received research support from NIH. Dr. Westover has received publishing royalties from a publication relating to health care. Dr. Westover has a non-compensated relationship as a cofounder with Beacon Biosignals that is relevant to AAN interests or activities.
Charles Matouk Charles Matouk has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Silk Road Medical. Charles Matouk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Microvention. Charles Matouk has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Navigantis.
Nils Petersen, MD (Yale University) The institution of Dr. Petersen has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Silkroad Medical. Dr. Petersen has received research support from NIH.
Emily J. Gilmore, MD (Yale University School of Medicine) Dr. Gilmore has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for carpl.ai. Dr. Gilmore has received personal compensation in the range of $0-$499 for serving as a Consultant for AAN. Dr. Gilmore has received research support from NIH.
Jennifer A. Kim, MD (Yale University School of Medicine) Dr. Kim has nothing to disclose.